Heart Vessels. 2006;21:33–7.VX-661 PubMedCrossRef 23. Townsend DM, Tew KD, Tapiero H. The importance of glutathione in human disease. Pharmacother. 2003;57:145–55.CrossRef 24. Ullmann KS, Northrop JP, Verweij CL, Crabtree GR. Transmission of signals

from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: the missing link. Annu Rev Immunol. 1990;8:421–52.CrossRef 25. Cu A, Ye Q, Sarria R, et al. N-acetylcysteine PKC inhibitor inhibits TNF-alpha, sTNFR, and TGF-beta1 release by alveolar macrophages in idiopathic pulmonary fibrosis in vitro. Sarcoidosis Vasc Diffuse Lung Dis. 2009;26:147–54.PubMed 26. Meurer SK, Lahme B, Tihaa L, Weiskirchen R, Gressner AM. N-acetyl-l-cysteine suppresses TGF-b signaling at distinct molecular steps: the biological efficacy of a multifunctional, antifibrotic drug. Biochem Pharmacol. 2005;70:1026–34.PubMedCrossRef 27. Sugiura H, Ichikawa T, Liu X, et al. N-acetyl-l-cysteine

inhibits TGF-beta1-induced profibrotic responses in fibroblasts. Pulm Pharmacol Ther. 2009;22:487–91.PubMedCrossRef 28. Zhang Y, Zhao J, Lau WB, et al. Tumor necrosis factor-α and lymphotoxin-α mediate myocardial ischemic injury selleck kinase inhibitor via TNF receptor 1, but are cardioprotective when activating TNF receptor 2. PLoS One. 2013;8:e60227.PubMedCrossRef 29. Panek AN, Posch MG, Alenina N, et al. Connective tissue growth factor overexpression in cardiomyocytes promotes cardiac hypertrophy and protection against pressure overload. PLoS One. 2009;4:e6743.PubMedCrossRef 30. Campbell SE, Katwa LC. Angiotensin II stimulated expression of transforming growth factor-beta1 in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol. 1997;29:1947–58.PubMedCrossRef 31. Stefanon I, Valero-Muñoz M, Fernandes AA, et al. Left and right ventricle late remodeling following myocardial infarction in rats. PLoS One. 2013;8:e64986.PubMedCrossRef 32. Herder C, Zierer A, Koenig W, et al. Transforming growth factor-beta1 and incident type 2 diabetes: results from the MONICA/KORA case-cohort study, 1984-2002. Diabetes Care. 2009;32:1921–3.PubMedCrossRef 33. Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes?

Diabetologia. 2005;48:1038–50.PubMedCrossRef 34. Massague J, Chen YG. Controlling TGF-beta signaling. Genes Dev. 2000;14:627–44.PubMed 35. Schultz Jel J, Witt SA, Glascock BJ, et al. TGF-beta1 mediates enough the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest. 2002;109:787–96.PubMed 36. Yagi S, Aihara K, Ikeda Y, et al. Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency. Circ Res. 2008;102:68–76.PubMedCrossRef 37. Lee SW, Hong MK, Lee CW, et al. Early and late clinical outcomes after primary stenting of the unprotected left main coronary artery stenosis in the setting of acute myocardial infarction. Int J Cardiol. 2004;97:73–6.PubMedCrossRef 38. Tang HC, Wong A, Wong P, et al.